関連する実験動画
Updated: Feb 18, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
1.0K
ステロイド耐性腎症候群における治療結果と進行中の小児臨床試験
Chris K Fan1, Heather S Jung1, Yasmine E Pang1
1Division of Pediatric Nephrology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Pediatric nephrology (Berlin, Germany)
|February 16, 2026
まとめ
新しい治療法は,ステロイド耐性腎不全症候群 (SRNS) を患っている子供に希望を与え,腎不全のリスクが高い状態です. このレビューは,小児性SRNSに対する新しい治療法と進行中の臨床試験をカバーしています.
科学分野:
- 小児腎臓病理学について
- 遺伝学 遺伝学とは
- 免疫学 免疫学とは
背景:
- 小児におけるステロイド耐性腎症候群 (SRNS) は,高い治療抵抗率と腎不全への進行とともに,重大な課題を提示しています.
- SRNSのモノジェニック形態と免疫抑制剤に対する耐性は,小児患者にとって最大のリスクである.
- SRNSの病原性を理解することは,ターゲットを絞った治療法の開発に不可欠です.
研究 の 目的:
- 小児のSRNSに関するコホート研究からの現代的な発見をレビューする.
- 新規の治療薬とその特定のメカニズム的標的を要約する.
- 小児SRNSに関する最近のおよび進行中の臨床試験の概要を紹介する.
主な方法:
- 現代のコホート研究に関する文献レビュー.
- SRNSにおける新しい治療薬とその標的の分析.
- 最近の臨床試験と現在進行中の臨床試験のデータを集めたものです.
主要な成果:
- SRNSの病原性を理解するうえでの進歩は,新しい標的治療法をもたらしました.
- 新薬は,SRNSに関与する遺伝的,免疫的,代謝的経路に対処します.
- 最近進行中の8つの臨床試験では,これらの新しいアプローチを評価しています.
結論:
- 課題があるにもかかわらず,小児性SRNSに対する新しい治療法は有望である.
- 標的型治療は,腎不全のリスクの高い子供たちに新しい希望をもたらします.
- 進行中の臨床試験は,小児のSRNS管理を進めるために不可欠です.
キーワード:
子供 子供 子供 子供 子供 子供焦点セグメンタルグルメロスクレロシスグローメルーロネフライト グローメルーロネフライト免疫抑制剤は,免疫を抑制する薬です.腎不全症候群 腎不全症候群 腎不全症候群 腎不全症候群精密医療とは予後予測 予後予測さらに関連する動画
関連する概念動画
01:26Nephrotic Syndrome II : Assessment and Medical Management
257
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
257
01:24Nephrotic Syndrome III : Nursing Management
358
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
358
01:24Nephrotic Syndrome I : Introduction
705
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
705
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
284
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
284
01:11Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
538
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
538